Table 1.
Clinical and morphological features of 55 patients with t(14;18)− FL
| Case | Sex | Age, y | Biopsy site | Cytological grading | Growth pattern | BCL2 | BCL6 | CD10 | CD23 | Ki67*, % | Stage | Clinical course |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FL1 | M | 61 | Cervical LN | 1-2 | Fo | − | + | + | − | 20 | IIEB | Relapse after 70 and 144 mo NED after 242 mo |
| FL2 | F | 73 | Axillary LN | 3A | Fo | − | + | − | − | 70 | NA | LFU |
| FL3† | M | 49 | Submandibular LN | 1-2 | Fo | − | + | + | − | 25 | IA | NED after 99 mo |
| FL4 | F | 50 | Inguinal LN | 3A | F/D | − | + | + | + | 50 | IA | NED after 81 mo |
| FL5† | F | 62 | Axillary LN | 1-2 | Fo | − | + | + | − | 15 | IIIA | Relapse after 43 mo NED after 150 mo |
| FL6 | F | 65 | Axillary LN | 1-2 | Fo | − | + | + | + | 15 | NA | LFU |
| FL7 | F | 72 | Axillary LN | 1-2 | Fo | − | + | + | + | 10 | IIIA | Relapse after 75 mo NED after 118 mo |
| FL8 | F | 53 | Inguinal LN | 1-2 | F/D | − | + | + | + | 10 | IA | NED after 5 mo after that LFU |
| FL9 | F | 79 | LN | 1-2 | Fo | − | + | − | − | 10 | NA | Relapse after 60 mo after that LFU |
| FL10 | M | 72 | Axillary LN | 1-2 | D | − | + | + | + | 30 | IIIA | Relapse after 2, 81 and 87 mo after that LFU |
| FL11 | F | 65 | Inguinal LN | 1-2 | F/D | − | + | + | + | 30 | IA | NED after 92 mo |
| FL12 | F | 79 | Inguinal LN | 1-2 | Fo | − | + | + | − | 30 | IA | NED after 79 mo |
| FL13 | F | 61 | LN | 1-2 | Fo | − | + | + | − | 10 | IV | No response, died with DLBCL after 10 mo |
| FL14 | M | 49 | Left inguinal LN | 1-2 | Fo | − | + | + | + | 10 | II | NED after 19 mo |
| FL15 | M | 45 | Inguinal LN | 1-2 | D | − | + | − | + | 35 | II | NED after 17 mo |
| FL16 | M | 60 | LN | 1-2 | Fo | (+) | + | + | − | 60 | IA | NED after 12 mo |
| FL17 | F | 56 | Inguinal LN | 1-2 | D | − | + | + | + | 30 | IA | NED after 8 mo |
| FL18† | F | 65 | Intraabdominal LN | 1-2 | Fo | − | + | + | − | 20 | IV | Watch and wait, no known progression after 7 mo |
| FL21 | M | 64 | Right inguinal LN | 1-2 | F/D | − | + | + | + | 10 | IA | NED after 166 mo |
| FL22† | F | 68 | Cervical LN | 1-2 | Fo | + | + | + | − | 50 | IIIB | DOD (72 mo) |
| FL23† | M | 45 | Left inguinal LN | 3A | Fo | (+) | + | (+) | − | 40 | IA | NED after 94 mo |
| FL24 | F | 50 | Axillary LN | 1-2 | Fo | − | + | + | − | 25 | IIIB | NED after 189 mo |
| FL25 | F | 46 | Inguinal LN | 1-2 | D | − | + | + | + | 10 | IA | NED after 41 mo |
| FL26 | F | 77 | Cervical LN | 1-2 | Fo | − | + | − | − | 15 | IA | NED after 42 mo |
| FL27 | F | 79 | Axillary LN | 1-2 | Fo | − | + | + | + | 70 | IA | NED after 19 mo |
| FL28 | F | 72 | Right axilla LN | 1-2 | Fo | − | + | + | + | 30 | NA | NA |
| FL29 | F | 52 | Left inguinal LN | 1-2 | F/D | − | + | + | + | 30 | NA | NA |
| FL30 | M | 42 | Right cervical LN | 3A | Fo | − | + | (+) | − | 75 | NA | NA |
| FL31 | M | 50 | Right axilla LN | 1-2 | D | − | + | + | + | 20 | NA | NA |
| FL32 | M | 80 | Inguinal LN | 3A | F/D | − | (+) | − | − | 30 | NA | NA |
| FL33 | F | 78 | Right axilla LN | 1-2 | Fo | − | + | + | − | 20 | NA | NA |
| FL34 | M | 33 | Inguinal LN | 1-2 | F/D | − | + | + | + | 30 | NA | NA |
| FL35† | M | 69 | Right cervical LN | 3A | Fo | − | + | − | − | 60 | NA | NA |
| FL36 | F | 77 | Right cervical LN | 1-2 | Fo | − | + | + | − | 20 | NA | NA |
| FL37† | F | 60 | Left inguinal LN | 1-2 | Fo | − | + | + | + | 10 | IA | NED after 88 mo |
| FL38† | F | 53 | Axillary LN | 1-2 | Fo | − | + | + | + | 30-35 | II | Relapse after 48 mo NED after 63 mo |
| FL39 | M | 68 | Inguinal LN | 1-2 | Fo | − | + | + | + | 30 | IA | NED after 30 mo |
| FL40 | F | 68 | Axillary LN | 1-2 | Fo | − | + | + | − | 20 | IA | NED after 94 mo |
| FL41 | F | 53 | Inguinal LN | 1-2 | F/D | − | + | + | + | 20 | IA | Relapse after 81 mo NED after 180 mo |
| FL42 | F | 74 | Inguinal LN | 1-2 | Fo | − | + | + | − | 80 | IVA | NED after 18 mo |
| FL44 | F | 49 | Inguinal LN | 1-2 | D | − | + | + | + | 45 | IA | NED after 24 mo |
| FL45 | F | 42 | Inguinal LN | 1-2 | Fo | − | + | + | + | 35 | IA | Relapse after 24 mo NED after 48 mo |
| FL46 | F | 81 | Inguinal LN | 1-2 | Fo | (+) | + | + | + | 35 | IA | NED after 24 mo |
| FL52† | F | 76 | Inguinal LN | 1-2 | Fo | − | + | − | + | 10-15 | IVA | NED after 53 mo |
| FL54† | M | 80 | Inguinal, cervical and axillary LN | 3A | Fo | − | + | − | − | 80 | IV | Dead after 3 mo |
| FL57 | M | 46 | Inguinal LN | 1-2 | D | − | + | + | − | 20-30 | IA | NED after 27 mo |
| FL58 | F | 46 | Axillary LN | 1-2 | Fo | − | + | − | + | <10 | IA | NED after 18 mo |
| FL59 | F | 87 | Submandibular LN | 1-2 | Fo | − | + | + | + | 80-90 | IA | NED after 3 mo |
| FL60 | F | 49 | Inguinal LN | 1-2 | D | − | + | + | + | 10 | IA | NED after 11 mo |
| FL62 | M | 61 | Inguinal LN | 1-2 | D | − | + | + | + | 15 | NA | NA |
| FL63 | F | 56 | Inguinal LN | 1-2 | D | + | + | + | + | 40 | IIIE | NED after 109 mo |
| FL64 | F | 63 | Inguinal LN | 1-2 | D | − | + | + | + | 25 | III | NED after 84 mo |
| FL65 | M | 63 | Inguinal LN | 1-2 | D | − | + | + | + | 15-20 | IA | NED after 62 mo |
| FL66 | F | 51 | Inguinal LN | 1-2 | D | − | + | + | + | 20 | NA | Relapse after 28 mo NED after 56 mo |
| FL67 | F | 61 | Inguinal LN | 1-2 | D | − | + | + | + | 10 | IA | NED after 51 mo |
D, diffuse; DOD, death of disease; F, female; F/D, follicular and diffuse; Fo, follicular; LFU, lost to follow-up; M, male; NA, not available; ND, not done; NED, no evidence of disease; +, positive; (+), weakly and heterogeneously positive; −, negative.
*
The median proliferation rate of grades 1 and 2 is 20% (range, 10%-90%), whereas the rate in grade 3A is 65% (range, 30%-80%).
†
BCL6 translocation.